You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A universal vaccine for the prevention of meningococcal meningitis in Africa

    SBC: OMVAX INC            Topic: R

    For more than years sub Saharan Africa has suffered with high rates of endemic meningococcal disease and periodic epidemic epidemics involving over cases In a low cost serogroup A polysaccharide protein conjugate vaccine MenAfriVac was introduced in the region The vaccine confers protection against serogroup A MenA disease as well as asymptomatic nasopharyngeal MenA carria ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Simvastatin nanomedicine in ARDS and sepsis

    SBC: EUNOIA BIOTECH LLC            Topic: 400

    Title Simvastatin nanomedicine in ARDS and sepsis The host response to severe infection termed sepsis affects more than million Americans yr generating annual direct costs exceeding $ billion Novel therapies are sorely needed to target maladaptive features of the host response that complement antimicrobial drugs and advances in supportive care Microcirculatory hyperpermeability may be a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: NCI

    PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    SBC: ZoneOne Pharma            Topic: O

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Novel sigma-2 receptor modulators for the treatment of cognitive dysfunction

    SBC: COGNITION THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION provided by applicant Cognition Therapeutics Inc andapos s mission is to develop effective therapeutics for Alzheimerandapos s disease AD Recent scientific discoveries have identified oligomers of the brain protein A as toxic culprits in disease progression Cognition in partnership with Temple University has identified a novel series of sigma receptor binding modulators t ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Treatment of Acute Radiation Syndrome using PIF, a Natural Immune Modulator

    SBC: BioIncept, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Recent nuclear accidents and threats have highlighted the growing risk of widespread radiation exposure causing a potentially devastating public health emergency Acute radiation syndrome ARS develops after total body or partial body irradiation at a moderate to high dose and is especially damaging to the immune system Damage to the skin gut and central n ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Real-Time Oxygen Monitoring for Tissue Health: Peripheral Artery Disease Application

    SBC: PROFUSA, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance

    SBC: EXSCIEN CORPORATION            Topic: NIDDK

    DESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Protection and Treatment of the Ocular Surface Barrier

    SBC: PROTERIS BIOTECH, INC.            Topic: N

    DESCRIPTION provided by applicant Dry eye a group of disorders that affects million people over the age of in the USA today is characterized by inadequate hydration and lubrication of the ocular surface The final common pathway for all types of dry eye is disruption of the ocular surface barrier which can be assessed by quantifying uptake of water soluble dyes applied topically to the ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Mechanistic Studies of a Novel Small Molecule HIV Inhibitor

    SBC: ADVANCED GENETIC SYSTEMS, INC.            Topic: 100

    DESCRIPTION provided by applicant There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens The Rev RRE protein RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it can be translated or packaged Previously we identified the thienopyridine scaffold that inhibited HIV ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government